Key Publications

Engler JB, Kursawe N, Solane ME, Patas K, Wehrmann S, Heckmann N, Lühder F, Reichart HM, Arck PC, Gold SM, Friese MA

Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy

Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):E181-E190.

Gold SM, Enck P, Hasselmann H, Friede T, Hegerl U, Mohr DC, Otte C

Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework.

Lancet Psychiatry

Weygandt M, Meyer-Arndt L, Behrens JR, Wakonig K, Bellmann-Strobl J, Ritter K, Scheel M, Brandt AU, Labadie C, Hetzer S, Gold SM, Paul F, Haynes JD.

Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis.

Proc. Natl. Acad. Sci. USA 2016

Ufer F, Vargas P, Engler JB, Tintelnot J, Schattling B, Winkler H, Bauer S, Kursawe N, Willing A, Keminer O, Ohana O, Salinas-Riester G, Pless O, Kuhl D, Friese MA.

Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation

Sci. Immunol. 2016 Sep;1:eaaf8665

Fischer A, Schröder J, Vettorazzi E, Wolf OT, Pöttgen J, Lau S, Heesen C, Moritz S, Gold SM.

An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial.

Lancet Psychiatry 2015;2:217-23.

Stellmann JP, Stürner KH, Young KL, Siemonsen S, Friede T, Heesen C.

Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts – Is There a Place for Baseline-to-Treatment Studies in MS?

PLoS ONE 2015;10:e0116559.

Köpke S, Kern S, Ziemssen T, Berghoff M, Kleiter I, Marziniak M, Paul F, Vettorazzi E, Pöttgen J, Fischer K, Kasper J, Heesen C.

Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial.

J. Neurol. Neurosurg. Psychiatr. 2014;85:411-8.

Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, Flockerzi V, Brück W, Pongs O, Vennekens R, Kneussel M, Freichel M, Merkler D, Friese MA.

TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis.

Nat. Med. 2012;18:1805-11.

Gold SM, Kern KC, O'Connor MF, Montag MJ, Kim A, Yoo YS, Giesser BS, Sicotte NL.

Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Biol. Psychiatry 2010;68:553-9.

Köpke S, Kasper J, Mühlhauser I, Nübling M, Heesen C.

Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.

Mult. Scler. 2009;15:96-104.

Friese MA, Jakobsen KB, Friis L, Etzensperger R, Craner MJ, McMahon RM, Jensen LT, Huygelen V, Jones EY, Bell JI, Fugger L.

Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis.

Nat. Med. 2008;14:1227-35.

Kasper J, Köpke S, Mühlhauser I, Nübling M, Heesen C.

Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial.

Eur. J. Neurol. 2008;15:1345-52.

Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, Vincent A, Fugger L.

Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.

Nat. Med. 2007;13:1483-9.

Original Articles

Engler JB, Kursawe N, Solane ME, Patas K, Wehrmann S, Heckmann N, Lühder F, Reichart HM, Arck PC, Gold SM, Friese MA

Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy

Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):E181-E190.

Thaler C, Faizy TD, Sedlacik J, Holst B, Stuerner KH, Heesen C, Stellmann JP, Fiehler J, Siemonsen S

T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.

AJNR Am J Neuroradiol. 2017 Feb;38(2):264-269

Faizy TD, Thaler C, Ceyrowski T, Broocks G, Sedlacik J, Stuerner KH, Stellmann JP, Heesen C, Fiehler J, Siemonsen S

Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period.

PLoS One. 2017 Feb 24;12(2):e0172923

Hodecker SC, Stellmann JP, Rosenkranz SC, Young K, Holst B, Friese MA, Heesen C

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 3;4(2);e328

Hodecker SC, Stuerner KH, Becker V, Elias-Hamp B, Holst B, Friese MA, Heesen C

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar;4(2);e325

Wendebourg MJ, Heesen C, Finlayson M, Meyer B, Pöttgen J, Köpke S

Patient education for people with multiple sclerosis-associated fatigue: A systematic review.

PLoS One. 2017 Mar 7;12(3)

Gold SM, Enck P, Hasselmann H, Friede T, Hegerl U, Mohr DC, Otte C

Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework.

Lancet Psychiatry

Heesen C, Kleiter I, Meuth Sven G, Krämer J, Kasper J, Köpke S, Gaissmaier W

Benefit-risk perception of natalizumab therapy in neurologists and a larger cohort of multiple sclerosis patients

J Neurol Sci. 2017 May 15;376;181-190

Krämer J, Tenberg JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG

Is the risk of progressive multifocal leukoencephalopathy the real reason for Natalizumab discontinuation in patients with multiple sclerosis?

PLoS One. 2017 Apr 13;12(4):e0174858

Stellmann JP, Young KL, Vettorazzi E, Pöttgen J, Heesen C

No relevant impact of ambient temperature on disability measurements in a large cohort of patients with multiple sclerosis.

Eur J Neurol. 2017 Jun;24(6):851-857

Kasper J, Liethmann K, Heesen C, Reissmann DR, Geiger F

Training doctors briefly and in situ to involve their patients in making medical decisions-Preliminary testing of a newly developed module.

Health Expect. 2017 May 18

Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group.

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.

Mult Scler. 2016 Oct 6;23(8):1092-1103

Weygandt M, Wakonig K, Behrens J, Meyer-Arndt L, Söder E, Brandt AU, Bellmann-Strobl J, Ruprecht K, Gold SM, Haynes JD, Paul F

Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.

Mult Scler. 2017 Jun 1 (epub ahead of print)

Gaissmaier W, Giese H, Galesic M, Garcia-Retamero R, Kasper J, Kleiter I, Meuth SG, Köpke S, Heesen C

Numeracy of multiple sclerosis patients: A comparison of patients from the PERCEPT study to a German probabilistic sample.

Patient Educ Couns. 2017 July 17

Kjolhede T, Siemonsen S, Wenzel D, Stellmann JP, Ringgaard S, Pedersen BG, Stenager E, Petersen T, Vissing K, Heesen C, Dalgas U

Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?

Mult Scler. 2017 Jul 1

Motl RW, Sandroff BM, Kwakkel G, Dalgas U, Feinstein A, Heesen C, Feys P, Thompson AJ

Exercise in patients with multiple sclerosis.

Lancet Neurol. 2017 Oct;16(10):848-856

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647

Stellmann JP, Hodecker S, Cheng B, Wanke N, Young KL, Hilgetag C, Gerloff C, Heesen C, Thomalla G, Siemonsen S.

Reduced rich-club connectivity is related to disability in primary progressive MS.

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 27;4(5):e375

Giovannetti AM, Giordano A, Pietrolongo E, Confalonieri P, De Luca G, Tortorella C, Trojano M, Messmer Uccelli M, Torri Clerici V, Gitto L, Köpke S, Borreani C, Heesen C, Solari A2 ManTra project.

Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy.

BMJ Open. 2017 Aug 23;7(8):e017254

Thomalla G, Boutitie F, Fiebach JB, Simonsen CZ, Nighoghossian N, Pedraza S, Lemmens R, Roy P, Muir KW, Heesen C, Ebinger M, Ford I, Cheng B, Cho TH, Puig J, Thijs V, Endres M, Fiehler J, Gerloff C.

Effect of informed consent on patient characteristics in a stroke thrombolysis trial.

Neurology. 2017 Sep 26;89(13):1400-1407

Rosenkranz SC, Kaulen B, Neuhaus A, Siemonsen S, Köpke S, Daumer M, Stellmann JP, Heesen C

Low clinical conversion rate in clinically isolated syndrome (CIS) patients – diagnostic benefit of McDonald 2010 criteria?

Eur J Neurol. 2017 Oct 11

von Gumberz J, Mahmoudi M, Young K, Schippling S, Martin R, Heesen C, Siemonsen S, Stellmann JP.

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting.

PeerJ. 2016 Sep 20;4:e2442

Sühs KW, Papanagiotou P, Hein K, Pul R, Scholz K, Heesen C, Diem R.

Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin

Int. J. Mol. Sci. 2016, 17, 1666

Weygandt M, Meyer-Arndt L, Behrens JR, Wakonig K, Bellmann-Strobl J, Ritter K, Scheel M, Brandt AU, Labadie C, Hetzer S, Gold SM, Paul F, Haynes JD.

Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis.

Proc. Natl. Acad. Sci. USA 2016

Riemann-Lorenz K, Eilers Marlene, Geldern Gloria von, Schulz KH, Köpke S, Heesen C

Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program

PloS One 2016 Oct 20;11(10)

Chavarro VS, Mealy, Maureen A, Sipson A, Lacheta A, Pache F, Ruprecht K, Gold SM, Paul F, Brandt AU, Levy, M

Insufficient treatment of severe depression in neuromyelitis optica sepctrum disorder

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 24;3(6)

Schattling B, Fazeli W, Engeland B, Liu Y, Lerche H, Isbrandt D, Friese MA

Activity of NaV1.2 promotes neurodegeneration in an animal model of multiple sclerosis

JCI Insight. 2016;1(19):e89810

Kasper J, van de Roemer A, Pöttgen J, Rahn A, Backhus I, Bay Y, Köpke S, Heesen C

A new graphical format to communicate treatment effects to patients-A web-based randomized controlled trial.

Health Expect. 2016 Dec 16

Stellmann JP, Cetin H, Young KL, Hodecker S, Pöttgen J, Bittersohl D, Hassenstein A, Oberwahrenbrock T, Heesen C, Siemsonsen S

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing-remitting MS.

Brain Behav. 2016 Dec 20;7(2):e00614.

Hasselmann H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, Rose M, Otte C, Adli M, Paul F, Brandt AU, Finke C, Gold SM.

Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression.

Mult Scler. 2016 Oct;22(11):1476-1484

Galler S, Stellmann JP, Young KL, Kutzner D, Heesen C, Fiehler J, Siemonsen S

Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis.

AJNR Am J Neuroradiol. 2016 Jan 7

Zeidman LA, von Villiez A, Stellmann JP, van den Bussche H

„History had taken such a large piece out of my life“ – Neuroscientist refugees from Hamburg during National Socialism.

J Hist Neurosci. 2016 Jul-Sep;25(3):275-98

Köpke S, Kasper J, Flachenecker P, Meißner H, Brandt A, Hauptmann B, Bender G, Backhus I, Rahn AC, Pöttgen J, Vettorazzi E, Heesen C.

Patient education programme on immunotherapy in multiple sclerosis (PEPIMS): A controlled rater-blinded study.

Clin Rehabil. 2016 Apr 12

Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Sühs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze WA.

Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.

BMJ Open. 2016 Mar 1;6(3)

Faizy TD, Thaler C, Kumar D, Sedlacik J, Broocks G, Grosser M, Stellmann JP, Heesen C, Fiehler J, Siemonsen S.

Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging.

PLoS One. 2016 Mar 18;11(3)

Rühl G, Niedl AG, Patronov A, Siewert K, Pinkert S, Kalemanov M, Friese MA, Attfield KE, Antes I, Hohlfeld R, Dornmair K

Multiple Sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor

Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(4)

Wendebourg MJ, Feddersen LK, Lau S, Köpke S, Moss-Morris R, Heesen C, Pöttgen J

Development and Feasibility of an Evidence-Based Patient Education Program for Managing Fatigue in Multiple Sclerosis: The „Fatigue Management in MS“ Program (FatiMa)

Int J MS Care. 2016 May-Jun;18(3):129-37

Krebs CF, Turner JE, Paust HJ, Kapffer S, Koyro T, Krohn S, Ufer F, Friese MA, Flavell RA, Stockinger B, Steinmetz OM, Stahl RA, Huber S, Panzer U.

Plasticity of Th17 Cells in Autoimmune Kidney Diseases.

J Immunol. 2016 Jul 15;197(2):449-57

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Sci Adv. 2016 Jun 17;2(6)

Stellmann JP, Jlussi M, Neuhaus A, Lederer C, Daumer M, Heesen C

Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.

J Neurol Sci. 2016 Sep 15;368:318-25

Riechel C, Alegiani AC, Köpke S, Kasper J, Rosenkranz M, Thomalla G, Heesen C

Subjective and objective knowledge and decisional role preferences in cerebrovascular patients compared to controls.

Patient Prefer Adherence. 2016 Aug 2;10:1453-60

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF

Major depressive disorder.

Nat Rev Dis Primers. 2016 Sep 15;2:16065

Sven Briken, Sina Cathérine Rosenkranz, Oliver Keminer, Stefan Patra, Gesche Ketels, Christoph Heesen, Rainer Hellweg, Ole Pless, Karl-Heinz Schulz, Stefan M. Gold

Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.

J. Neuroimmunol. 2016 Oct 15;299:53-58

Ufer F, Vargas P, Engler JB, Tintelnot J, Schattling B, Winkler H, Bauer S, Kursawe N, Willing A, Keminer O, Ohana O, Salinas-Riester G, Pless O, Kuhl D, Friese MA.

Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation

Sci. Immunol. 2016 Sep;1:eaaf8665

Rahn AC, Backhus I, Fuest F, Riemann-Lorenz K, Köpke S, van de Roemer A, Mühlhauser I, Heesen C.

Comprehension of confidence intervals – development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial

BMC Med Inform Decis Mak. 2016 Sep 20;16(1):122.

Stellmann J, Young K, Pöttgen J, Dorr M, Heesen C.

Introducing a new method to assess vision: Computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients

MSJ 2015;1:1-8

Piédavent-Salomon M, Willing A, Engler JB, Steinbach K, Bauer S, Eggert B, Ufer F, Kursawe N, Wehrmann S, Jäger J, Reinhardt S, Friese MA.

Multiple sclerosis associated genetic variants of CD226 impair regulatory T cell function.

Brain. 2015 Nov;138(Pt 11):3263-74

Stellmann JP, Stürner KH, Ufer F, Havemeister S, Pöttgen J, Ayuk Ayuketang F, Kröger N, Friese MA, Heesen C.

Stem cell transplantation for multiple sclerosis : Hamburg experiences and state of international research.

Nervenarzt 2015;86:989-96.

Fischer A, Schröder J, Vettorazzi E, Wolf OT, Pöttgen J, Lau S, Heesen C, Moritz S, Gold SM.

An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial.

Lancet Psychiatry 2015;2:217-23.

Geertz W, Dechow AS, Patra S, Heesen C, Gold SM, Schulz KH.

Changes of Motivational Variables in Patients with Multiple Sclerosis in an Exercise Intervention: Associations between Physical Performance and Motivational Determinants.

Behav Neurol 2015;2015:248193.

Kern KC, Gold SM, Lee B, Montag M, Horsfall J, O'Connor MF, Sicotte NL.

Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.

Neuroimage Clin 2015;8:440-7.

Michailidou I, Willems JG, Kooi EJ, van Eden C, Gold SM, Geurts JJ, Baas F, Huitinga I, Ramaglia V.

Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus.

Ann. Neurol. 2015;77:1007-26.

Pöttgen J, Lau S, Penner I, Heesen C, Moritz S.

Managing Neuropsychological Impairment in Multiple Sclerosis: Pilot Study on a Standardized Metacognitive Intervention.

Int J MS Care 2015;17:130-7.

Del Piccolo L, Pietrolongo E, Radice D, Tortorella C, Confalonieri P, Pugliatti M, Lugaresi A, Giordano A, Heesen C, Solari A, .

Patient expression of emotions and neurologist responses in first multiple sclerosis consultations.

PLoS ONE 2015;10:e0127734.

Siemonsen S, Young KL, Bester M, Sedlacik J, Heesen C, Fiehler J, Stellmann JP.

Chronic T2 Lesions in Multiple Sclerosis are Heterogeneous Regarding Phase MR Imaging.

Clin Neuroradiol 2015.

Stellmann JP, Neuhaus A, Götze N, Briken S, Lederer C, Schimpl M, Heesen C, Daumer M.

Ecological validity of walking capacity tests in multiple sclerosis.

PLoS ONE 2015;10:e0123822.

Rahn AC, Köpke S, Kasper J, Vettorazzi E, Mühlhauser I, Heesen C.

Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.

Trials 2015;16:106.

Bester M, Forkert ND, Stellmann JP, Aly L, Drabik A, Young KL, Heesen C, Fiehler J, Siemonsen S.

Increased perfusion in normal appearing white matter in high inflammatory multiple sclerosis patients.

PLoS ONE 2015;10:e0119356.

Siemonsen S, Brekenfeld C, Holst B, Kaufmann-Buehler AK, Fiehler J, Bley TA.

3T MRI Reveals Extra- and Intracranial Involvement in Giant Cell Arteritis.

AJNR Am J Neuroradiol 2015;36:91-7.

Ernst M, Forkert ND, Brehmer L, Thomalla G, Siemonsen S, Fiehler J, Kemmling A.

Prediction of Infarction and Reperfusion in Stroke by Flow- and Volume-Weighted Collateral Signal in MR Angiography.

AJNR Am J Neuroradiol 2015;36:275-82.

Stellmann JP, Stürner KH, Young KL, Siemonsen S, Friede T, Heesen C.

Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts – Is There a Place for Baseline-to-Treatment Studies in MS?

PLoS ONE 2015;10:e0116559.

Heesen C, Kasper J, Fischer K, Köpke S, Rahn A, Backhus I, Poettgen J, Vahter L, Drulovic J, Van Nunen A, Beckmann Y, Liethmann K, Giordano A, Fulcher G, Solari A; AutoMS-group.

Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0) – Development of an Outcome Instrument for Educational Interventions.

PLoS ONE 2015;10:e0138364

Planas R, Metz I, Ortiz Y, Vilarrasa N, Jelcíc I, Salinas-Riester G, Heesen C, Brück W, Martin R, Sospedra M.

Central Role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions.

Ann. Neurol. 2015;2(9):875-93

Fischer A, Fischer M, Nicholls RA, Lau S, Poettgen J, Patas K, Heesen C, Gold SM.

Diagnostic accuracy for major depression in multiple sclerosis using self-report questionnaires.

Brain Behav. 2015;9:e00365

Kumar D, Siemonsen S, Heesen C, Fiehler J, Sedlacik J.

Noise robust spatially regularized myelin water fraction mapping with the intrinsic B1 -error correction based on the linearized version of the extended phase graph model.

Journal of Magnetic Resonance Imaging

Hertwig L, Pache F, Romero-Suarez S, Stürner KH, Borisow N, Behrens J, Bellmann-Strobl J, Seeger B, Asselborn N, Ruprecht K, Millward JM, Infante-Duarte C, Paul F.

Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica.

Mult Scler. 2015

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Genet Epidemiol. 2015;39:601-8

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group.

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

Ann Neurol. 2015

Thaler C , Faizy T, Sedlacik J, Holst B, Stellmann JP, Young KL, Heesen C, Fiehler J, Siemonsen S.

T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.

PLoS One. 2015;10(12):e0144693

Gersing AS, Faymonville AM, Schwaiger BJ, Leypoldt F, Siemonsen S, Zimmer C, Magnus T, Fiehler J.

Quantitative T2* mapping reveals early temporo-spatial dynamics in an ischemic stroke model.

J Neurosci Methods. 2016;259:83-9

Fischer A, Grundmann J, Gold SM, Spitzer C, Wingenfeld K.

Steroid regulation of T cell function appears unaltered in borderline personality disorder.

J Pers Disord. 2015 Apr;29(2):241-7

Gold SM, O'Connor MF, Gill R, Kern KC, Shi Y, Henry RG, Pelletier D, Mohr DC, Sicotte NL.

Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling.

Hum Brain Mapp 2014;35:30-7.

Sedlacik J, Boelmans K, Löbel U, Holst B, Siemonsen S, Fiehler J.

Reversible, irreversible and effective transverse relaxation rates in normal aging brain at 3T.

Neuroimage 2014;84:1032-41.

Köpke S, Kern S, Ziemssen T, Berghoff M, Kleiter I, Marziniak M, Paul F, Vettorazzi E, Pöttgen J, Fischer K, Kasper J, Heesen C.

Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial.

J. Neurol. Neurosurg. Psychiatr. 2014;85:411-8.

Briken S, Gold SM, Patra S, Vettorazzi E, Harbs D, Tallner A, Ketels G, Schulz KH, Heesen C.

Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.

Mult. Scler. 2014;20:382-90.

Siemonsen S, Forkert ND, Hansen A, Kemmling A, Thomalla G, Fiehler J.

Spatial distribution of perfusion abnormality in acute MCA occlusion is associated with likelihood of later recanalization.

J. Cereb. Blood Flow Metab. 2014;34:813-9.

Galinovic I, Puig J, Neeb L, Guibernau J, Kemmling A, Siemonsen S, Pedraza S, Cheng B, Thomalla G, Fiehler J, Fiebach JB.

Visual and region of interest-based inter-rater agreement in the assessment of the diffusion-weighted imaging- fluid-attenuated inversion recovery mismatch.

Stroke 2014;45:1170-2.

Stellmann JP, Neuhaus A, Lederer C, Daumer M, Heesen C.

Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.

PLoS ONE 2014;9:e92761.

Cheng B, Forkert ND, Zavaglia M, Hilgetag CC, Golsari A, Siemonsen S, Fiehler J, Pedraza S, Puig J, Cho TH, Alawneh J, Baron JC, Ostergaard L, Gerloff C, Thomalla G.

Influence of stroke infarct location on functional outcome measured by the modified rankin scale.

Stroke 2014;45:1695-702.

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M.

A vaccine targeting mutant IDH1 induces antitumour immunity.

Nature 2014;512:324-7.

Willing A, Leach OA, Ufer F, Attfield KE, Steinbach K, Kursawe N, Piedavent M, Friese MA.

CD8⁺ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis.

Eur. J. Immunol. 2014;44:3119-28.

Verleger T, Schönfeld M, Säring D, Siemonsen S, Fiehler J, Forkert ND.

Aligning 3D time-of-flight MRA datasets for quantitative longitudinal studies: evaluation of rigid registration techniques.

Magn Reson Imaging 2014;32:1390-5.

Stellmann JP, Vettorazzi E, Poettgen J, Heesen C.

A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients.

J. Neurol. Sci. 2014;346:99-106.

Gelderblom M, Melzer N, Schattling B, Göb E, Hicking G, Arunachalam P, Bittner S, Ufer F, Herrmann AM, Bernreuther C, Glatzel M, Gerloff C, Kleinschnitz C, Meuth SG, Friese MA, Magnus T.

Transient receptor potential melastatin subfamily member 2 cation channel regulates detrimental immune cell invasion in ischemic stroke.

Stroke 2014;45:3395-402.

Fischer A, Grundmann J, Gold SM, Spitzer C, Wingenfeld K.

Steroid Regulation of T Cell Function Appears Unaltered in Borderline Personality Disorder.

J. Pers. Disord. 2014:1-7.

Brand J, Köpke S, Kasper J, Rahn A, Backhus I, Poettgen J, Stellmann JP, Siemonsen S, Heesen C.

Magnetic resonance imaging in multiple sclerosis–patients‘ experiences, information interests and responses to an education programme.

PLoS ONE 2014;9:e113252.

Hofmann A, Stellmann JP, Kasper J, Ufer F, Elias WG, Pauly I, Repenthin J, Rosenkranz T, Weber T, Köpke S, Heesen C, .

Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.

Mult. Scler. 2013;19:920-5.

Avouac J, Elhai M, Tomcik M, Ruiz B, Friese M, Piedavent M, Colonna M, Bernhardt G, Kahan A, Chiocchia G, Distler JH, Allanore Y.

Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis.

Ann. Rheum. Dis. 2013;72:1089-98.

Choe CU, Karamatskos E, Schattling B, Leypoldt F, Liuzzi G, Gerloff C, Friese MA, Mulert C.

A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder.

Psychiatry Res 2013;208:194-6.

Pöttgen J, Dziobek I, Reh S, Heesen C, Gold SM.

Impaired social cognition in multiple sclerosis.

J. Neurol. Neurosurg. Psychiatr. 2013;84:523-8.

Galea I, Lederer C, Neuhaus A, Muraro PA, Scalfari A, Koch-Henriksen N, Heesen C, Koepke S, Stellmann P, Albrecht H, Winkelmann A, Weber F, Bahn E, Hauser M, Edan G, Ebers G, Daumer M.

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.

Eur. J. Neurol. 2013;20:1107-9.

Schäffler N, Schönberg P, Stephan J, Stellmann JP, Gold SM, Heesen C.

Comparison of patient-reported outcome measures in multiple sclerosis.

Acta Neurol. Scand. 2013;128:114-21.

Hinkelmann K, Muhtz C, Dettenborn L, Agorastos A, Moritz S, Wingenfeld K, Spitzer C, Gold SM, Wiedemann K, Otte C.

Association between cortisol awakening response and memory function in major depression.

Psychol Med 2013;43:2255-63.

Østergaard L, Jespersen SN, Mouridsen K, Mikkelsen IK, Jonsdottír KÝ, Tietze A, Blicher JU, Aamand R, Hjort N, Iversen NK, Cai C, Hougaard KD, Simonsen CZ, Von Weitzel-Mudersbach P, Modrau B, Nagenthiraja K, Riisgaard Ribe L, Hansen MB, Bekke SL, Dahlman MG, Puig J, Pedraza S, Serena J, Cho TH, Siemonsen S, Thomalla G, Fiehler J, Nighoghossian N, Andersen G.

The role of the cerebral capillaries in acute ischemic stroke: the extended penumbra model.

J. Cereb. Blood Flow Metab. 2013;33:635-48.

Forkert ND, Kaesemann P, Treszl A, Siemonsen S, Cheng B, Handels H, Fiehler J, Thomalla G.

Comparison of 10 TTP and Tmax estimation techniques for MR perfusion-diffusion mismatch quantification in acute stroke.

AJNR Am J Neuroradiol 2013;34:1697-703.

Pietrolongo E, Giordano A, Kleinefeld M, Confalonieri P, Lugaresi A, Tortorella C, Pugliatti M, Radice D, Goss C, Heesen C, Solari A, .

Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments.

PLoS ONE 2013;8:e60721.

Heesen C, Gaissmaier W, Nguyen F, Stellmann JP, Kasper J, Köpke S, Lederer C, Neuhaus A, Daumer M.

Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool.

PLoS ONE 2013;8:e59042.

Lutterotti A, Yousef S, Sputtek A, Stürner KH, Stellmann JP, Breiden P, Reinhardt S, Schulze C, Bester M, Heesen C, Schippling S, Miller SD, Sospedra M, Martin R.

Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.

Sci Transl Med 2013;5:188ra75.

Solari A, Giordano A, Kasper J, Drulovic J, van Nunen A, Vahter L, Viala F, Pietrolongo E, Pugliatti M, Antozzi C, Radice D, Köpke S, Heesen C, .

Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale.

PLoS ONE 2013;8:e66127.

Gelderblom M, Daehn T, Schattling B, Ludewig P, Bernreuther C, Arunachalam P, Matschke J, Glatzel M, Gerloff C, Friese MA, Magnus T.

Plasma levels of neuron specific enolase quantify the extent of neuronal injury in murine models of ischemic stroke and multiple sclerosis.

Neurobiol. Dis. 2013;59:177-82.

Steinbach K, Piedavent M, Bauer S, Neumann JT, Friese MA.

Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs.

J. Immunol. 2013;191:4531-9.

Köpke S, Richter T, Kasper J, Mühlhauser I, Flachenecker P, Heesen C.

Implementation of a patient education program on multiple sclerosis relapse management.

Patient Educ Couns 2012;86:91-7.

Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C.

Treatment of steroid-unresponsive optic neuritis with plasma exchange.

Acta Neurol. Scand. 2012;126:103-8.

MacKenzie-Graham A, Rinek GA, Avedisian A, Gold SM, Frew AJ, Aguilar C, Lin DR, Umeda E, Voskuhl RR, Alger JR.

Cortical atrophy in experimental autoimmune encephalomyelitis: in vivo imaging.

Neuroimage 2012;60:95-104.

Reitz LY, Inglese M, Fiehler J, Finsterbusch J, Holst B, Heesen C, Martin R, Schippling S.

Quantitative T2′ imaging in patients with clinically isolated syndrome.

Acta Neurol. Scand. 2012;126:357-63.

Spitzer C, Bouchain M, Winkler LY, Wingenfeld K, Gold SM, Grabe HJ, Barnow S, Otte C, Heesen C.

Childhood trauma in multiple sclerosis: a case-control study.

Psychosom Med 2012;74:312-8.

Fischer A, Otte C, Krieger T, Nicholls RA, Krüger S, Ziegler KJ, Schulz KH, Heesen C, Gold SM.

Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression.

Psychoneuroendocrinology 2012;37:1712-8.

Siemonsen S, Fitting T, Thomalla G, Krützelmann A, Fiehler J.

Visual assessment of magnetic resonance imaging perfusion lesions in a large patient group.

Clin Neuroradiol 2012;22:305-13.

Siemonsen S, Löbel U, Sedlacik J, Forkert ND, Mouridsen K, Østergaard L, Thomalla G, Fiehler J.

Elevated T2-values in MRI of stroke patients shortly after symptom onset do not predict irreversible tissue infarction.

Brain 2012;135:1981-9.

Kasper J, Hoffmann F, Heesen C, Köpke S, Geiger F.

MAPPIN’SDM–the multifocal approach to sharing in shared decision making.

PLoS ONE 2012;7:e34849.

Sasidhar MV, Itoh N, Gold SM, Lawson GW, Voskuhl RR.

The XX sex chromosome complement in mice is associated with increased spontaneous lupus compared with XY.

Ann. Rheum. Dis. 2012;71:1418-22.

Gold SM, Sasidhar MV, Lagishetty V, Spence RD, Umeda E, Ziehn MO, Krieger T, Schulz KH, Heesen C, Hewison M, Voskuhl RR.

Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation.

J. Clin. Endocrinol. Metab. 2012;97:E1402-10.

Kasper J, Köpke S, Fischer K, Schäffler N, Backhus I, Solari A, Heesen C.

Applying the theory of planned behaviour to multiple sclerosis patients‘ decisions on disease modifying therapy–questionnaire concept and validation.

BMC Med Inform Decis Mak 2012;12:60.

Kasper J, Hoffmann F, Heesen C, Köpke S, Geiger F.

Completing the third person’s perspective on patients‘ involvement in medical decision-making: approaching the full picture.

Z Evid Fortbild Qual Gesundhwes 2012;106:275-83.

Sühs KW, Hein K, Sättler MB, Görlitz A, Ciupka C, Scholz K, Käsmann-Kellner B, Papanagiotou P, Schäffler N, Restemeyer C, Bittersohl D, Hassenstein A, Seitz B, Reith W, Fassbender K, Hilgers R, Heesen C, Bähr M, Diem R.

A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.

Ann. Neurol. 2012;72:199-210.

Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, Orthey E, Arumugam TV, Leypoldt F, Simova O, Thom V, Friese MA, Prinz I, Hölscher C, Glatzel M, Korn T, Gerloff C, Tolosa E, Magnus T.

Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke.

Blood 2012;120:3793-802.

Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, Flockerzi V, Brück W, Pongs O, Vennekens R, Kneussel M, Freichel M, Merkler D, Friese MA.

TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis.

Nat. Med. 2012;18:1805-11.

Stellmann JP, Neuhaus A, Herich L, Schippling S, Roeckel M, Daumer M, Martin R, Heesen C.

Placebo cohorts in phase-3 MS treatment trials – predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.

PLoS ONE 2012;7:e50347.

Saitta L, Heese O, Förster AF, Matschke J, Siemonsen S, Castellan L, Westphal M, Fiehler J, Goebell E.

Signal intensity in T2′ magnetic resonance imaging is related to brain glioma grade.

Eur Radiol 2011;21:1068-76.

Schäffler N, Köpke S, Winkler L, Schippling S, Inglese M, Fischer K, Heesen C.

Accuracy of diagnostic tests in multiple sclerosis–a systematic review.

Acta Neurol. Scand. 2011;124:151-64.

Vergo S, Craner MJ, Etzensperger R, Attfield K, Friese MA, Newcombe J, Esiri M, Fugger L.

Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.

Brain 2011;134:571-84.

Tzartos JS, Craner MJ, Friese MA, Jakobsen KB, Newcombe J, Esiri MM, Fugger L.

IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain.

Am. J. Pathol. 2011;178:794-802.

Gold SM, Krüger S, Ziegler KJ, Krieger T, Schulz KH, Otte C, Heesen C.

Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression.

J. Neurol. Neurosurg. Psychiatr. 2011;82:814-8.

Leypoldt F, Friese MA, Böhm J, Bäumer T.

Multiple enlarged nerves on neurosonography: an unusual paraneoplastic case.

Muscle Nerve 2011;43:756-8.

Carrera E, Jones PS, Alawneh JA, Klærke Mikkelsen I, Cho TH, Siemonsen S, Guadagno JV, Mouridsen K, Ribe L, Hjort N, Fryer TD, Carpenter TA, Aigbirhio FI, Fiehler J, Nighoghossian N, Warburton EA, Ostergaard L, Baron JC.

Predicting infarction within the diffusion-weighted imaging lesion: does the mean transit time have added value?

Stroke 2011;42:1602-7.

McMahon RM, Friis L, Siebold C, Friese MA, Fugger L, Jones EY.

Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis.

Acta Crystallogr. D Biol. Crystallogr. 2011;67:447-54.

Möller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C.

HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis.

Mult. Scler. 2011;17:1002-9.

Alawneh JA, Jones PS, Mikkelsen IK, Cho TH, Siemonsen S, Mouridsen K, Ribe L, Morris RS, Hjort N, Antoun N, Gillard JH, Fiehler J, Nighoghossian N, Warburton EA, Ostergaard L, Baron JC.

Infarction of ‚non-core-non-penumbral‘ tissue after stroke: multivariate modelling of clinical impact.

Brain 2011;134:1765-76.

Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, Kappos L.

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.

Mult. Scler. 2011;17:1341-50.

Goebell E, Fiehler J, Siemonsen S, Vaeterlein O, Heese O, Hagel C, Ding XQ, Buhk JH, Groth M, Kucinski T.

Macromolecule content influences proton diffusibility in gliomas.

Eur Radiol 2011;21:2626-32.

Kasper J, Heesen C, Köpke S, Fulcher G, Geiger F.

Patients‘ and observers‘ perceptions of involvement differ. Validation study on inter-relating measures for shared decision making.

PLoS ONE 2011;6:e26255.

Kasper J, Heesen C, Köpke S, Mühlhauser I, Lenz M.

Why not? – Communicating stochastic information by use of unsorted frequency pictograms – a randomised controlled trial.

Psychosoc Med 2011;8:Doc08.

Gold SM, Schulz H, Stein H, Solf K, Schulz KH, Heesen C.

Responsiveness of patient-based and external rating scales in multiple sclerosis: head-to-head comparison in three clinical settings.

J. Neurol. Sci. 2010;290:102-6.

Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A.

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.

Brain 2010;133:1655-67.

Heesen C, Schulz KH, Fiehler J, Von der Mark U, Otte C, Jung R, Poettgen J, Krieger T, Gold SM.

Correlates of cognitive dysfunction in multiple sclerosis.

Brain Behav. Immun. 2010;24:1148-55.

Gold SM, Kern KC, O'Connor MF, Montag MJ, Kim A, Yoo YS, Giesser BS, Sicotte NL.

Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Biol. Psychiatry 2010;68:553-9.

Heesen C, Kleiter I, Nguyen F, Schäffler N, Kasper J, Köpke S, Gaissmaier W.

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.

Mult. Scler. 2010;16:1507-12.

Köpke S, Kasper J, Mühlhauser I, Nübling M, Heesen C.

Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.

Mult. Scler. 2009;15:96-104.

Kasper J, Heesen C, Mühlhauser I.

[Evidence-based patient information: the example of immunotherapy for patients with multiple sclerosis].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009;52:77-85.

Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C.

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.

Neurology 2009;72:1022-4.

Ries T, Siemonsen S, Grzyska U, Zeumer H, Fiehler J.

Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature.

Stroke 2009;40:1750-7.

Harkiolaki M, Holmes SL, Svendsen P, Gregersen JW, Jensen LT, McMahon R, Friese MA, van Boxel G, Etzensperger R, Tzartos JS, Kranc K, Sainsbury S, Harlos K, Mellins ED, Palace J, Esiri MM, van der Merwe PA, Jones EY, Fugger L.

T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides.

Immunity 2009;30:348-57.

Siemonsen S, Mouridsen K, Holst B, Ries T, Finsterbusch J, Thomalla G, Ostergaard L, Fiehler J.

Quantitative t2 values predict time from symptom onset in acute stroke patients.

Stroke 2009;40:1612-6.

Lange R, Volkmer M, Heesen C, Liepert J.

Modafinil effects in multiple sclerosis patients with fatigue.

J. Neurol. 2009;256:645-50.

Holst B, Siemonsen S, Finsterbusch J, Bester M, Schippling S, Martin R, Fiehler J.

T2′ imaging indicates decreased tissue metabolism in frontal white matter of MS patients.

Mult. Scler. 2009;15:701-7.

Fiehler J, Siemonsen S, Thomalla G, Illies T, Kucinski T.

Combination of T2*W and FLAIR abnormalities for the prediction of parenchymal hematoma following thrombolytic therapy in 100 stroke patients.

J Neuroimaging 2009;19:311-6.

Thomalla G, Rossbach P, Rosenkranz M, Siemonsen S, Krützelmann A, Fiehler J, Gerloff C.

Negative fluid-attenuated inversion recovery imaging identifies acute ischemic stroke at 3 hours or less.

Ann. Neurol. 2009;65:724-32.

Heesen C, Schäffler N, Kasper J, Mühlhauser I, Köpke S.

Suspected multiple sclerosis – what to do? Evaluation of a patient information leaflet.

Mult. Scler. 2009;15:1103-12.

Gold SM, Sasidhar MV, Morales LB, Du S, Sicotte NL, Tiwari-Woodruff SK, Voskuhl RR.

Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha).

Lab. Invest. 2009;89:1076-83.

Friese MA, Fugger L.

Pathogenic CD8(+) T cells in multiple sclerosis.

Ann. Neurol. 2009;66:132-41.

Kruetzelmann A, Siemonsen S, Gerloff C, Rosenkranz M, Röther J, Fiehler J, Thomalla G.

Thrombolysis targeting MRI defined tissue at risk in minor stroke.

J. Neurol. Neurosurg. Psychiatr. 2009;80:1156-8.

Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L.

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Am. J. Pathol. 2008;172:146-55.

Siemonsen S, Finsterbusch J, Matschke J, Lorenzen A, Ding XQ, Fiehler J.

Age-dependent normal values of T2* and T2′ in brain parenchyma.

AJNR Am J Neuroradiol 2008;29:950-5.

Thomalla G, Kruetzelmann A, Siemonsen S, Gerloff C, Rosenkranz M, Röther J, Fiehler J.

Clinical and tissue response to intravenous thrombolysis in tandem internal carotid artery/middle cerebral artery occlusion: an MRI study.

Stroke 2008;39:1616-8.

Bester M, Heesen C, Schippling S, Martin R, Ding XQ, Holst B, Fiehler J.

Early anisotropy changes in the corpus callosum of patients with optic neuritis.

Neuroradiology 2008;50:549-57.

Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM.

Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable.

Mult. Scler. 2008;14:988-91.

Siemonsen S, Fitting T, Thomalla G, Horn P, Finsterbusch J, Summers P, Saager C, Kucinski T, Fiehler J.

T2′ imaging predicts infarct growth beyond the acute diffusion-weighted imaging lesion in acute stroke.

Radiology 2008;248:979-86.

Gold SM, Chalifoux S, Giesser BS, Voskuhl RR.

Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone.

J Neuroinflammation 2008;5:32.

Bengner T, Siemonsen S, Stodieck S, Fiehler J.

T2 relaxation time correlates of face recognition deficits in temporal lobe epilepsy.

Epilepsy Behav 2008;13:670-7.

Friese MA, Jakobsen KB, Friis L, Etzensperger R, Craner MJ, McMahon RM, Jensen LT, Huygelen V, Jones EY, Bell JI, Fugger L.

Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis.

Nat. Med. 2008;14:1227-35.

Kasper J, Köpke S, Mühlhauser I, Nübling M, Heesen C.

Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial.

Eur. J. Neurol. 2008;15:1345-52.

Schippling S, Heesen C, Zander A, Martin R.

Stem cell transplantation in multiple sclerosis.

J. Neurol. 2008;255 Suppl 6:43-7.

Dziobek I, Gold SM, Wolf OT, Convit A.

Hypercholesterolemia in Asperger syndrome: independence from lifestyle, obsessive-compulsive behavior, and social anxiety.

Psychiatry Res 2007;149:321-4.

Fiehler J, Geisler B, Siemonsen S, Saager C, Speck O, Thomalla G, Grzyska U, Kucinski T.

[Visual rating of T2′-blood-oxygen-level-dependent magnetic resonance imaging in acute stroke patients–a pilot study].

Rofo 2007;179:17-20.

Gold SM, Dziobek I, Sweat V, Tirsi A, Rogers K, Bruehl H, Tsui W, Richardson S, Javier E, Convit A.

Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes.

Diabetologia 2007;50:711-9.

Heesen C, Köpke S, Richter T, Kasper J.

Shared decision making and self-management in multiple sclerosis–a consequence of evidence.

J. Neurol. 2007;254 Suppl 2:II116-21.

Pöhlau D, Przuntek H, Sailer M, Bethke F, Koehler J, König N, Heesen C, Späth P, Andresen I.

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.

Mult. Scler. 2007;13:1107-17.

Ries T, Siemonsen S, Thomalla G, Grzyska U, Zeumer H, Fiehler J.

Long-term follow-up of cerebral aneurysms after endovascular therapy prediction and outcome of retreatment.

AJNR Am J Neuroradiol 2007;28:1755-61.

Hamann J, Neuner B, Kasper J, Vodermaier A, Loh A, Deinzer A, Heesen C, Kissling W, Busch R, Schmieder R, Spies C, Caspari C, Härter M.

Participation preferences of patients with acute and chronic conditions.

Health Expect 2007;10:358-63.

Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, Vincent A, Fugger L.

Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.

Nat. Med. 2007;13:1483-9.

Hamann J, Loh A, Kasper J, Neuner B, Spies C, Kissling W, Härter M, Heesen C.

[Effects of a shared decision making model in psychiatric and neurologic practice].

Nervenarzt 2006;77:1071-6, 1078.

Kasper J, Köpke S, Mühlhauser I, Heesen C.

Evidence-based patient information about treatment of multiple sclerosis–a phase one study on comprehension and emotional responses.

Patient Educ Couns 2006;62:56-63.

Aulwurm S, Wischhusen J, Friese M, Borst J, Weller M.

Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.

Int. J. Cancer 2006;118:1728-35.

Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM.

Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?

J. Neurol. Neurosurg. Psychiatr. 2006;77:34-9.

Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA.

TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.

Brain 2006;129:2416-25.

Heesen C, Segal J, Reich C, Hämäläinen P, Broemel F, Niemann S, Simon U, Gross R, Kasper J.

Patient information on cognitive symptoms in multiple sclerosis – acceptability in relation to disease duration.

Acta Neurol. Scand. 2006;114:268-72.

Heesen C, Koehler G, Gross R, Tessmer W, Schulz KH, Gold SM.

Altered cytokine responses to cognitive stress in multiple sclerosis patients with fatigue.

Mult. Scler. 2005;11:51-7.

Gold SM, Dziobek I, Rogers K, Bayoumy A, McHugh PF, Convit A.

Hypertension and hypothalamo-pituitary-adrenal axis hyperactivity affect frontal lobe integrity.

J. Clin. Endocrinol. Metab. 2005;90:3262-7.

Gold SM, Raji A, Huitinga I, Wiedemann K, Schulz KH, Heesen C.

Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.

J. Neuroimmunol. 2005;165:186-91.

Liepert J, Mingers D, Heesen C, Bäumer T, Weiller C.

Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study.

Mult. Scler. 2005;11:316-21.

Friese MA, Fugger L.

Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?

Brain 2005;128:1747-63.

Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M.

HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo.

J. Neuropathol. Exp. Neurol. 2005;64:523-8.

Hoeller U, Rolofs K, Bajrovic A, Berger J, Heesen C, Pfeiffer G, Alberti W.

A patient questionnaire for radiation-induced brachial plexopathy.

Am. J. Clin. Oncol. 2004;27:1-7.

Gold SM, Zakowski SG, Valdimarsdottir HB, Bovbjerg DH.

Higher Beck depression scores predict delayed epinephrine recovery after acute psychological stress independent of baseline levels of stress and mood.

Biol Psychol 2004;67:261-73.

Schulz KH, Gold SM, Witte J, Bartsch K, Lang UE, Hellweg R, Reer R, Braumann KM, Heesen C.

Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis.

J. Neurol. Sci. 2004;225:11-8.

Giersdorf N, Loh A, Bieber C, Caspari C, Deinzer A, Doering T, Eich W, Hamann J, Heesen C, Kasper J, Leppert K, Müller K, Neumann T, Neuner B, Rohlfing H, Scheibler F, van Oorschot B, Spies C, Vodermaier A, Weiss-Gerlach E, Zysno P, Härter M, .

[Development and validation of assessment instruments for shared decision making].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004;47:969-76.

Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M.

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

Cancer Res. 2004;64:7596-603.

Heesen C, Kasper J, Segal J, Köpke S, Mühlhauser I.

Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis.

Mult. Scler. 2004;10:643-50.

Kucinski T, Koch C, Eckert B, Becker V, Krömer H, Heesen C, Grzyska U, Freitag HJ, Röther J, Zeumer H.

Collateral circulation is an independent radiological predictor of outcome after thrombolysis in acute ischaemic stroke.

Neuroradiology 2003;45:11-8.

Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C.

Effects of mitoxantrone on multiple sclerosis patients‘ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.

Eur. Neurol. 2003;49:137-41.

Gold SM, Zakowski SG, Valdimarsdottir HB, Bovbjerg DH.

Stronger endocrine responses after brief psychological stress in women at familial risk of breast cancer.

Psychoneuroendocrinology 2003;28:584-93.

Heesen C, Bruegmann M, Gbdamosi J, Koch E, Mönch A, Buhmann C.

Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone.

Mult. Scler. 2003;9:213-4.

Heesen C, Kolbeck J, Gold SM, Schulz H, Schulz KH.

Delivering the diagnosis of MS–results of a survey among patients and neurologists.

Acta Neurol. Scand. 2003;107:363-8.

Gold SM, Schulz KH, Hartmann S, Mladek M, Lang UE, Hellweg R, Reer R, Braumann KM, Heesen C.

Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls.

J. Neuroimmunol. 2003;138:99-105.

Friese MA, Manuelian T, Junnikkala S, Hellwage J, Meri S, Peter HH, Gordon DL, Eibel H, Zipfel PF.

Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis.

Clin. Exp. Immunol. 2003;132:485-95.

Mehnert F, Friese MA, Nägele T.

[Meningoencephalitis caused by Listeria monocytogenes].

Rofo 2003;175:1142-3.

Gold SM, Schulz H, Mönch A, Schulz KH, Heesen C.

Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures.

Mult. Scler. 2003;9:404-10.

Heesen C, Gold SM, Hartmann S, Mladek M, Reer R, Braumann KM, Wiedemann K, Schulz KH.

Endocrine and cytokine responses to standardized physical stress in multiple sclerosis.

Brain Behav. Immun. 2003;17:473-81.

Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M.

MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

Cancer Res. 2003;63:8996-9006.

Heesen C, Gold SM, Raji A, Wiedemann K, Schulz KH.

Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis.

Psychoneuroendocrinology 2002;27:505-17.

Heesen C, Schulz H, Schmidt M, Gold S, Tessmer W, Schulz KH.

Endocrine and cytokine responses to acute psychological stress in multiple sclerosis.

Brain Behav. Immun. 2002;16:282-7.

Heesen C, Gold SM, Bruhn M, Mönch A, Schulz KH.

Prolactin stimulation in multiple sclerosis–an indicator of disease subtypes and activity?

Endocr. Res. 2002;28:9-18.

Buhmann C, Gbadamosi J, Heesen C.

Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy.

Acta Neurol. Scand. 2002;106:236-9.

Heesen C, Gold SM, Sondermann J, Tessmer W, Schulz KH.

Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls.

J. Neuroimmunol. 2002;132:189-95.

Hellwage J, Jokiranta TS, Friese MA, Wolk TU, Kampen E, Zipfel PF, Meri S.

Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.

J. Immunol. 2002;169:6935-44.

Heesen C, Gbadamosi J, Schoser BG, Pöhlau D.

Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate–a case report.

Eur. J. Neurol. 2001;8:199.

Gold SM, Heesen C, Schulz H, Guder U, Mönch A, Gbadamosi J, Buhmann C, Schulz KH.

Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS).

Mult. Scler. 2001;7:119-30.

Gbadamosi J, Buhmann C, Moench A, Heesen C.

Failure of ondansetron in treating cerebellar tremor in MS patients–an open-label pilot study.

Acta Neurol. Scand. 2001;104:308-11.

Heesen C, Sieverding F, Buhmann C, Gbadamosi J.

IL-1ra serum levels in disease stages of MS–a marker for progression?

Acta Neurol. Scand. 2000;101:95-7.

Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S.

Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1.

J. Immunol. 2000;164:6075-81.

Friese MA, Hellwage J, Jokiranta TS, Meri S, Müller-Quernheim HJ, Peter HH, Eibel H, Zipfel PF.

Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA).

Clin. Exp. Immunol. 2000;121:406-15.

Heesen C, Georghiu S, Gbadamosi J, Schoser BG.

CD95-mediated apoptosis and DNA fragmentation in MS.

Acta Neurol. Scand. 2000;102:333-6.

Heesen C, Hauer S, Hadji-Abdolrahim B, Berenbeck C, Buhmann C, Emskotter T.

Current status of multiple sclerosis therapy in Germany: a national survey.

Eur. J. Neurol. 1999;6:35-8.

Heesen C, Sieverding F, Schoser BG, Hadji B, Kunze K.

Interleukin-12 is detectable in sera of patients with multiple sclerosis – association with chronic progressive disease course?

Eur. J. Neurol. 1999;6:591-6.

Friese MA, Hellwage J, Jokiranta TS, Meri S, Peter HH, Eibel H, Zipfel PF.

FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated.

Mol. Immunol. 1999;36:809-18.

Schoser BG, Heesen C, Eckert B, Thie A.

Cerebral hyperperfusion injury after percutaneous transluminal angioplasty of extracranial arteries.

J. Neurol. 1997;244:101-4.

Heesen C, Bergmann M, Figge C, Löschke S, Feldmann M.

[Intravascular lymphomatosis of the nervous system–case report and review of the literature].

Fortschr Neurol Psychiatr 1996;64:234-41.

Heesen C, Engler F.

[Immunological abnormalities in migraine and cluster headache-epiphenomenon or pathogenetic factors?].

Schmerz 1993;7:8-14.

Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL.

Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener’s granulomatosis. Association with disease activity.

Arthritis Rheum. 1992;35:1088-96.

Reviews

Ramien C, Taenzer A, Lupu A, Heckmann N, Engler JB, Patas K, Friese MA, Gold SM

Sex effects on inflammatory and neurodegenerative processes in multiple sclerosis.

Neurosci Biobehav Rev. 2016 Aug;67:137-46

Friese, MA

Widespread synaptic loss in multiple sclerosis.

Brain. 2016 Jan;139(Pt 1):2-4

Gold SM, Voskuhl RR

Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application.

Semin Immunopathol. 2016 Aug 8

Dendrou CA, Fugger L, Friese MA.

Immunopathology of multiple sclerosis.

Nat. Rev. Immunol. 2015;15:545-58.

Galea I, Ward-Abel N, Heesen C.

Relapse in multiple sclerosis.

BMJ 2015;350:h1765.

van Buel EM, Patas K, Peters M, Bosker FJ, Eisel UL, Klein HC

Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all?

Transl Psychiatry. 2015;5:e609

Heesen C, Cohen JA.

Does the patient know best? Quality of life assessment in multiple sclerosis trials.

Mult. Scler. 2014;20:131-2.

Friese MA, Schattling B, Fugger L.

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.

Nat Rev Neurol 2014;10:225-38.

Schattling B, Eggert B, Friese MA.

Acquired channelopathies as contributors to development and progression of multiple sclerosis.

Exp. Neurol. 2014;262 Pt A:28-36.

Köpke S, Solari A, Khan F, Heesen C, Giordano A.

Information provision for people with multiple sclerosis.

Cochrane Database Syst Rev 2014;4:CD008757.

Heesen C, Bruce J, Feys P, Sastre-Garriga J, Solari A, Eliasson L, Matthews V, Hausmann B, Ross AP, Asano M, Imonen-Charalambous K, Köpke S, Clyne W, Bissell P.

Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report.

Mult. Scler. 2014;20:1795-8.

Patas K, Engler JB, Friese MA, Gold SM.

Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity.

J. Reprod. Immunol. 2013;97:140-6.

Heesen C, Köpke S, Solari A, Geiger F, Kasper J.

Patient autonomy in multiple sclerosis–possible goals and assessment strategies.

J. Neurol. Sci. 2013;331:2-9.

Hellmann-Regen J, Piber D, Hinkelmann K, Gold SM, Heesen C, Spitzer C, Endres M, Otte C.

Depressive syndromes in neurological disorders.

Eur Arch Psychiatry Clin Neurosci 2013;263 Suppl 2:S123-36.

Voskuhl RR, Gold SM.

Sex-related factors in multiple sclerosis susceptibility and progression.

Nat Rev Neurol 2012;8:255-63.

Willing A, Friese MA.

CD8-mediated inflammatory central nervous system disorders.

Curr. Opin. Neurol. 2012;25:316-21.

Heesen C, Gold SM.

Don’t stress about it! Is stress management a disease-modifying therapy for multiple sclerosis?

Neurology 2012;79:398-9.

Heesen C, Köpke S, Kasper J, Poettgen J, Tallner A, Mohr DC, Gold SM.

Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.

Expert Rev Neurother 2012;12:1089-100.

Piber D, Hinkelmann K, Gold SM, Heesen C, Spitzer C, Endres M, Otte C.

[Depression and neurological diseases].

Nervenarzt 2012;83:1423-33.

Heesen C, Solari A, Giordano A, Kasper J, Köpke S.

Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement.

J. Neurol. Sci. 2011;306:192-7.

Friese MA, Magnus T.

[Autoimmune synaptic encephalopathies].

Nervenarzt 2011;82:1239-49.

Fischer A, Heesen C, Gold SM.

Biological outcome measurements for behavioral interventions in multiple sclerosis.

Ther Adv Neurol Disord 2011;4:217-29.

Friese MA.

[Multiple sclerosis].

Dtsch. Med. Wochenschr. 2010;135:527-31.

Heesen C.

Treating multiple sclerosis with information.

Mult. Scler. 2010;16:1302.

Gold SM, Irwin MR.

Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.

Immunol Allergy Clin North Am 2009;29:309-20.

Fugger L, Friese MA, Bell JI.

From genes to function: the next challenge to understanding multiple sclerosis.

Nat. Rev. Immunol. 2009;9:408-17.

Gold SM, Voskuhl RR.

Estrogen treatment in multiple sclerosis.

J. Neurol. Sci. 2009;286:99-103.

Gold SM, Voskuhl RR.

Estrogen and testosterone therapies in multiple sclerosis.

Prog. Brain Res. 2009;175:239-51.

Heesen C, Kasper J, Köpke S, Richter T, Segal J, Mühlhauser I.

Informed shared decision making in multiple sclerosis–inevitable or impossible?

J. Neurol. Sci. 2007;259:109-17.

Heesen C, Mohr DC, Huitinga I, Bergh FT, Gaab J, Otte C, Gold SM.

Stress regulation in multiple sclerosis: current issues and concepts.

Mult. Scler. 2007;13:143-8.

Heesen C, Gold SM, Huitinga I, Reul JM.

Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis – a review.

Psychoneuroendocrinology 2007;32:604-18.

Friese MA, Fugger L.

T cells and microglia as drivers of multiple sclerosis pathology.

Brain 2007;130:2755-7.

Heesen C, Romberg A, Gold S, Schulz KH.

Physical exercise in multiple sclerosis: supportive care or a putative disease-modifying treatment.

Expert Rev Neurother 2006;6:347-55.

Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L.

The value of animal models for drug development in multiple sclerosis.

Brain 2006;129:1940-52.

Gold SM, Voskuhl RR.

Testosterone replacement therapy for the treatment of neurological and neuropsychiatric disorders.

Curr Opin Investig Drugs 2006;7:625-30.

Gold SM, Irwin MR.

Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.

Neurol Clin 2006;24:507-19.

Friese MA, Jensen LT, Willcox N, Fugger L.

Humanized mouse models for organ-specific autoimmune diseases.

Curr. Opin. Immunol. 2006;18:704-9.

Gold SM, Heesen C.

Stress and disease progression in multiple sclerosis and its animal models.

Neuroimmunomodulation 2006;13:318-26.

Holmes S, Friese MA, Siebold C, Jones EY, Bell J, Fugger L.

Multiple sclerosis: MHC associations and therapeutic implications.

Expert Rev Mol Med 2005;7:1-17.

Köpke S, Heesen C.

Corticosteroids treatment of multiple sclerosis.

J. Neurol. Sci. 2005;234:117-8; author reply 119-20.

Schulz KH, Heesen C.

[Effects of exercise in chronically ill patients. Examples from oncology and neurology].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005;48:906-13.

Steckelberg A, Berger B, Köpke S, Heesen C, Mühlhauser I.

[Criteria for evidence-based patient information].

Z Arztl Fortbild Qualitatssich 2005;99:343-51.

Friese MA, Jones EY, Fugger L.

MHC II molecules in inflammatory diseases: interplay of qualities and quantities.

Trends Immunol. 2005;26:559-61.

Gold SM, Mohr DC, Huitinga I, Flachenecker P, Sternberg EM, Heesen C.

The role of stress-response systems for the pathogenesis and progression of MS.

Trends Immunol. 2005;26:644-52.

Schulz KH, Heesen C, Gold SM.

[The concept of allostasis and allostatic load: psychoneuroimmunological findings].

Psychother Psychosom Med Psychol 2005;55:452-61.

Köpke S, Heesen C, Kasper J, Mühlhauser I.

Steroid treatment for relapses in multiple sclerosis – the evidence urges shared decision-making.

Acta Neurol. Scand. 2004;110:1-5.

Friese MA, Steinle A, Weller M.

The innate immune response in the central nervous system and its role in glioma immune surveillance.

Onkologie 2004;27:487-91.

Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, et. al.

Escalating immunotherapy of multiple sclerosis–new aspects and practical application.

J. Neurol. 2004;251:1329-39.

Zipfel PF, Hellwage J, Friese MA, Hegasy G, Jokiranta ST, Meri S.

Factor H and disease: a complement regulator affects vital body functions.

Mol. Immunol. 1999;36:241-8.

Copyright 2015. Institute of Neuroimmunology and Multiple Sclerosis. Impressum